Illumina wants to bring liquid biopsy spinout Grail back in-house; reportCancer diagnosis firm Grail could be re-joining Illumina, the company it was spun out of in 2016, despite Share XIllumina wants to bring liquid biopsy spinout Grail back in-house; reporthttps://pharmaphorum.com/news/illumina-wants-to-bring-liquid-biopsy-spinout-grail-back-in-house-report/
Roche and Illumina forge genomics alliance for cancer testingRoche missed out on acquiring next-generation sequencing (NGS) specialist Illumina via a hostile takeover a few years back, Share XRoche and Illumina forge genomics alliance for cancer testinghttps://pharmaphorum.com/news/roche-and-illumina-forge-genomics-alliance-for-cancer-testing/
DNA sequencers Illumina and PacBio call off $1.2bn mergerCalifornia-based DNA sequencing firms Illumina and Pacific Biosciences have called off their proposed $1.2 billion merger, after deciding Share XDNA sequencers Illumina and PacBio call off $1.2bn mergerhttps://pharmaphorum.com/news/dna-sequencers-illumina-and-pacific-call-off-1-2-bn-merger/
Illumina picks UK site for biotech startup engineGenomics firm Illumina is to foster biotech innovation in the UK by establishing a branch of its “Illumina Share XIllumina picks UK site for biotech startup enginehttps://pharmaphorum.com/news/illumina-picks-uk-site-for-biotech-startup-engine/
Oxford Nanopore’s tech reaches genome sequencing landmarkOxford Nanopore one of many firms cutting time and cost of sequencing Share XOxford Nanopore’s tech reaches genome sequencing landmarkhttps://pharmaphorum.com/news/handheld-genome-sequencing-revolutionise-medicine/